Carl is a cofounder of A4P and Director and specialises in Biomarkers and Large Molecules.

Carl has extensive experience of designing, implementing and managing Biomarker strategies in human clinical trials across a range of therapeutic areas, including oncology,

respiratory and inflammation, utilising a range of technologies including Flow cytometry, IHC, gene expression profiling, mass spec and ligand binding methods.

Carl has experience of biomarkers from both the CRO and Pharma sides as a result of positions held with GSK, Pfizer and Serono amongst others.